Dott. Riccardo Nevola

Specialista in Medicina Interna, perfezionato in Epatologia. Ha conseguito il Dottorato di Ricerca in Scienze Cliniche, Mediche e Sperimentali presso l'Università degli Studi della Campania "L. Vanvitelli"

Attualmente Dirigente Medico presso la Unità Fegato - AORN Moscati Avellino

• Medicina Interna

• Università degli Studi della Campania Luigi Vanvitelli

• Italiano
• Inglese

• Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma (Biology, 2023 Jul)
• Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era? (Cancers, 2023 May)
• HBV Infection and Host Interactions: The Role in Viral Persistence and Oncogenesis (Int J Mol Sci, 2023 Apr)
• Predictors of early and late hepatocellular carcinoma recurrence (World J Gastroenterol, 2023 Feb)
• Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies (Biomedicines, 2023 Feb)
• Impact of chronic liver disease on SARS-CoV-2 infection outcomes: Roles of stage, etiology and vaccination (World J Gastroenterol, 2023 Feb)
• GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (Int J Mol Sci, 2023 Jan)
• Extrahepatic Manifestations of Chronic HBV Infection and the Role of Antiviral Therapy (J Clin Med, 2022 Oct)
• Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies (Biology, 2022 May)
• Telemedicine Improves HCV Elimination among Italian People Who Use Drugs: An Innovative Therapeutic Model to Increase the Adherence to Treatment into Addiction Care Centers Evaluated before and during the COVID-19 Pandemic (Biology, 2022 May)
• Elimination of Hepatitis C in Southern Italy: A Model of HCV Screening and Linkage to Care among Hospitalized Patients at Different Hospital Divisions (Viruses, 2022 May)
• Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic-Standardized National Screening or One Tailored to Local Epidemiology? (Biology, 2022 Apr)
• Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study (J Viral Hepat, 2022 Jan)
• A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy (Viruses, 2021 Nov)
• Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience (Am J Gastroenterol, 2021 Jun)
• Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes (Nutr Metab Cardiovasc Dis, 2021 Jul)
• Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals (Expert Rev Gastroenterol Hepatol, 2021 Jun)
• Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study (Life, 2020 Dec)
• Unusual liver-related heart injury (JGH Open, 2020 Jun)
• Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study (PLoS One, 2020 Dec)
• Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: mechanisms and management (Minerva Med, 2021 Apr)
• Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals (JGH Open, 2020 Mar)
• Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study (Diabetes Obes Metab, 2020 Dec)
• Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics (Cancers, 2020 May)
• HCC in HCV patients and the direct acting antivirals: is there really a link? (Eur Rev Med Pharmacol Sci, 2020 Jan)
• Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study (Atherosclerosis, 2020 Mar)
• Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study (J Transl Med, 2019 Aug)
• Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience (Dig Dis Sci, 2019 Oct)
• Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments? (World J Gastroenterol, 2018 Nov)
• Endotoxinemia contributes to steatosis, insulin resistance and atherosclerosis in chronic hepatitis C: the role of pro-inflammatory cytokines and oxidative stress (Infection, 2018 Dec)
• Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis (J Hepatol, 2018 Jul)
• Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients (J Gastroenterol Hepatol, 2018 Jul)
• Chronic Hepatitis C Virus Infection and Depression (Clin Liver Dis, 2017 Aug)
• Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis (World J Gastroenterol, 2017 Feb)
• Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview (World J Gastroenterol, 2015 Feb)
• nsulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression (World J Hepatol, 2014 Sep)

• Epatite C
• Cirrosi epatica
• Epatite B
• Tumore del fegato
• Epatocarcinoma
• Colestasi
• Calcolosi della colecisti
• Ipertensione portale
• Malattie autoimmuni
• Epatite delta
• Colangite biliare primitiva
• Colangite sclerosante primitiva
• Epatite cronica da alcol